Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2014 1
2015 1
2016 1
2017 4
2018 5
2019 5
2020 3
2021 6
2022 3
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. Farge D, et al. Lancet Oncol. 2022 Jul;23(7):e334-e347. doi: 10.1016/S1470-2045(22)00160-7. Lancet Oncol. 2022. PMID: 35772465 Free PMC article. Review.
Individualized Pazopanib Dosing-Letter.
Bellesoeur A, Boudou-Rouquette P, Thomas-Schoemann A, Joly C, Tlemsani C, Vidal M, Goldwasser F, Blanchet B. Bellesoeur A, et al. Clin Cancer Res. 2017 Oct 15;23(20):6377. doi: 10.1158/1078-0432.CCR-17-1873. Clin Cancer Res. 2017. PMID: 29030334 No abstract available.
Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.
Puszkiel A, Noé G, Bellesoeur A, Kramkimel N, Paludetto MN, Thomas-Schoemann A, Vidal M, Goldwasser F, Chatelut E, Blanchet B. Puszkiel A, et al. Among authors: bellesoeur a. Clin Pharmacokinet. 2019 Apr;58(4):451-467. doi: 10.1007/s40262-018-0703-0. Clin Pharmacokinet. 2019. PMID: 30094711 Review.
Advances in theranostic biomarkers for tumor immunotherapy.
Bellesoeur A, Torossian N, Amigorena S, Romano E. Bellesoeur A, et al. Curr Opin Chem Biol. 2020 Jun;56:79-90. doi: 10.1016/j.cbpa.2020.02.005. Epub 2020 Mar 24. Curr Opin Chem Biol. 2020. PMID: 32217357 Review.
[Homologous recombination deficiency and PARP inhibitors in therapeutics].
Salaün H, Saint-Ghislain M, Bellesoeur A, Beuzeboc P, Neuzillet C, Diéras V, Stern MH, Rodrigues M. Salaün H, et al. Among authors: bellesoeur a. Bull Cancer. 2022 Jan;109(1):76-82. doi: 10.1016/j.bulcan.2021.09.015. Epub 2021 Nov 17. Bull Cancer. 2022. PMID: 34799081 Review. French.
Adverse events of targeted therapies approved for women's cancers.
Saint-Ghislain M, Levenbruck C, Bellesoeur A. Saint-Ghislain M, et al. Among authors: bellesoeur a. Int J Womens Dermatol. 2021 Oct 27;7(5Part A):552-559. doi: 10.1016/j.ijwd.2021.10.006. eCollection 2021 Dec. Int J Womens Dermatol. 2021. PMID: 35024412 Free PMC article. Review.
Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy.
Malhaire C, Selhane F, Saint-Martin MJ, Cockenpot V, Akl P, Laas E, Bellesoeur A, Ala Eddine C, Bereby-Kahane M, Manceau J, Sebbag-Sfez D, Pierga JY, Reyal F, Vincent-Salomon A, Brisse H, Frouin F. Malhaire C, et al. Among authors: bellesoeur a. Eur Radiol. 2023 Nov;33(11):8142-8154. doi: 10.1007/s00330-023-09797-5. Epub 2023 Jun 15. Eur Radiol. 2023. PMID: 37318605
34 results